Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a universal CAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory neurological autoimmune diseases, with recruitment ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis
• Inflammatory Demyelinating Polyneuropathy
• Multiple Sclerosis
• Myasthenia Gravis
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• UCAR T-cell therapy targeting CD19 and BCMA (Universal CAR T-cell therapy targeting CD19 and BCMA)

Snippet

Sponsor: Tianjin Huanhu Hospital | Conditions: Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis | EARLY_Phase 1 | Status: RECRUITING